| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medicine (C.W., R.S.), Harbor-University of California, Los Angeles Medical Center and Research and Education Institute, Torrance, California 90509-2910; Diabetes and Glandular Disease Research Associates (M.K.), San Antonio, Texas 78229-3894; Department of Medicine (A.M.M.), University of Washington, Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98195; Department of Medicine (A.S.D.), Johns Hopkins University, Baltimore, Maryland 21287-4904; Department of Medicine (G.C.), Baylor University School of Medicine, Houston, Texas 77030; Department of Medicine (L.K.), Massachusetts General Hospital, Boston, Massachusetts 02114; Department of Medicine (T.J.W.), Duke University Medical Center, Durham, North Carolina 27705; Division of Endocrinology (T.C.F.), Department of Medicine, Charles Drew University of Medicine, Los Angeles, California 90059; Department of Medicine (P.S.), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6087; and Columbia Laboratories, Inc. (H.L.L.), Livingston, New Jersey 07039
Address all correspondence and requests for reprints to: Dr. Christina Wang, General Clinical Research Center Box 16, Harbor-University of California Los Angeles Medical Center, 1000 West Carson Street, Torrance, California 90509. E-mail: wang{at}gcrc.rei.edu.
A new mucoadhesive testosterone buccal system (Striant), 30 mg testosterone (T), was applied twice daily in 82 hypogonadal men for 3 months. Serum T, free T, and 5
-dihydrotestosterone were measured during this period. T pharmacokinetics were determined from the data obtained during a 24-h sampling at wk 12. Physiological mean serum T concentrations were steady and consistently maintained. The mean percentage of time over a 24-h period that total serum T concentrations were above the lower limit of adult male range was 80.1%. During treatment, mean serum 5
-dihydrotestosterone, free T, and estradiol concentrations paralleled serum T. T pharmacokinetics were not significantly affected by body mass index, age, food or beverage, gum abnormalities, or medications known to cause dry mouth. Gum-related adverse events occurred in 16.3% of subjects. Except for three subjects, the gum adverse effects occurred early during treatment, did not cause interruption of treatment, and resolved rapidly and completely. The T buccal system is a novel T formulation that offers a safe, effective, and convenient alternative to existing formulations for physiological T replacement therapy in hypogonadal men.
This work was supported by Columbia Laboratories, Inc. (Livingston, NJ) and General Clinical Research Center at Harbor-University of California Los Angeles Medical Center (MO1RR00425).
This work was presented in part at the 84th Annual Meeting of The Endocrine Society, San Francisco, California, June, 2002.
Abbreviations: AUC, Area under the curve; BMI, body mass index; Cavg, average serum T levels over a 24-h period; CV, coefficient of variation; DHT, dihydrotestosterone; E2, estradiol; PK, pharmacokinetics; T, testosterone; TBS, T buccal system.
This article has been cited by other articles:
![]() |
M. Wald, M. Miner, and A. D. Seftel State of the Art Reviews: Male Menopause: Fact or Fiction? American Journal of Lifestyle Medicine, April 1, 2008; 2(2): 132 - 141. [Abstract] [PDF] |
||||
![]() |
M. Wald, R. B. Meacham, L. S. Ross, and C. S. Niederberger Testosterone Replacement Therapy for Older Men J Androl, March 1, 2006; 27(2): 126 - 132. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |